Gabapentin is a prescription medication used in the United States for certain seizure disorders and nerve pain. The drug is available generically and has also been sold under brand names including Neurontin. Over the years, gabapentin and Neurontin have been connected with several different types of litigation, ranging from illegal off-label marketing allegations to antitrust disputes and individual product-liability claims.
It is important, however, to distinguish the historic Neurontin litigation from newer advertisements suggesting that a large nationwide gabapentin lawsuit is currently underway. As of August 2026, the best-documented large-scale federal litigation involving Neurontin primarily concerns earlier marketing, sales practices, product-liability, and antitrust disputes. Official federal records reviewed do not establish a new nationwide gabapentin personal-injury mass tort comparable with major active drug MDLs such as Roundup or some other pharmaceutical litigations.
Why Were Gabapentin and Neurontin Lawsuits Filed?
Some of the most important gabapentin litigation arose from the way Neurontin was marketed for uses that had not been approved by the U.S. Food and Drug Administration.
Warner-Lambert, which was later acquired by Pfizer, marketed Neurontin. Federal authorities alleged that the company’s Parke-Davis division promoted the drug for several unapproved uses, including certain psychiatric conditions, pain conditions, migraines, and other indications.
The issue was not simply that doctors prescribed the medicine off-label. Doctors may legally prescribe approved medications for off-label purposes when they consider it medically appropriate. The government’s case focused instead on allegations that the manufacturer unlawfully promoted the drug for uses that the FDA had not approved.
The $430 Million Neurontin Settlement
One of the largest historical developments occurred in 2004.
Warner-Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities connected with the promotion of Neurontin for unapproved uses.
The U.S. Department of Justice stated that the resolution included a $240 million criminal fine. Additional payments addressed federal and state civil liabilities associated with the marketing practices and Medicaid claims.
The settlement became one of the most prominent pharmaceutical marketing enforcement cases of its period and continues to play an important role in discussions about the history of gabapentin litigation.
Kaiser Lawsuit Against Pfizer Over Neurontin Marketing
Private health insurers and other organizations also pursued litigation related to Neurontin.
One particularly significant case involved Kaiser Foundation Health Plan and Pfizer. Kaiser alleged that fraudulent promotion caused it to pay for Neurontin prescriptions for certain off-label uses.
A jury awarded Kaiser approximately $47.4 million. Because the case involved claims under the federal Racketeer Influenced and Corrupt Organizations Act, or RICO, the award was trebled to approximately $142.1 million.
In 2013, the U.S. Court of Appeals for the First Circuit upheld the verdicts in Kaiser’s favor. Related litigation was also pursued by insurers including Aetna.
Gabapentin Side Effects and FDA Safety Warnings
Product-liability discussions involving gabapentin often focus on whether patients received adequate warnings about serious potential risks.
The FDA has warned that gabapentin can cause serious breathing difficulties in certain patients, particularly when the medication is taken with opioids or other drugs that depress the central nervous system. People with underlying respiratory problems and elderly patients can also face greater risks.
Current FDA-approved Neurontin labeling also contains warnings concerning suicidal thoughts or behavior associated with antiepileptic drugs, serious hypersensitivity reactions, and respiratory depression. Reports of respiratory depression and sedation, sometimes resulting in death, have been associated with gabapentin taken together with opioids.
These warnings do not mean that every person who experiences a medical problem while taking gabapentin automatically has a valid lawsuit. A product-liability plaintiff normally has to establish a legally recognized defect or failure to warn and show that it caused the claimed injury.
Are There Gabapentin Dementia Lawsuits in 2026?
Some legal-marketing websites in 2026 have begun discussing possible gabapentin claims involving dementia, cognitive impairment, or memory problems. These discussions appear to have been influenced in part by newer research examining possible associations between long-term gabapentin exposure and cognitive outcomes.
However, claims that a major nationwide “gabapentin dementia lawsuit” or established mass tort already exists should be treated cautiously.
Federal court and Judicial Panel on Multidistrict Litigation records reviewed through August 2026 document the older Neurontin marketing and product-liability proceedings, including MDL No. 1629, but they do not establish a newly centralized nationwide gabapentin-dementia MDL.
Research suggesting an association between a medicine and a health condition also does not by itself establish legal causation. Plaintiffs pursuing such cases would still have to prove issues including exposure, injury, causation, warning adequacy, and manufacturer responsibility.
What Types of Gabapentin Lawsuits May Be Filed?
Depending on the circumstances and applicable state law, a person alleging injury from gabapentin could potentially pursue several product-liability theories.
A failure-to-warn claim may allege that a manufacturer failed to provide adequate information about a serious risk associated with the medication. Other cases may allege defective design, negligence, misrepresentation, or breach of warranty.
A wrongful death claim could also potentially arise when surviving family members allege that a drug-related injury contributed to a patient’s death, although the requirements for wrongful death actions vary considerably from state to state.
The earlier Neurontin litigation also demonstrates that gabapentin-related disputes are not limited to personal injuries. Previous cases have involved fraudulent marketing, health-insurer reimbursement, RICO allegations, and antitrust claims concerning competition from generic gabapentin.
Gabapentin Lawsuit Settlements and Current Status
There is no single settlement amount that applies to every gabapentin lawsuit.
The best-known government resolution remains Warner-Lambert’s more than $430 million settlement from 2004. Kaiser later obtained a judgment exceeding $140 million in its private litigation relating to off-label Neurontin marketing. These figures involved specific allegations and should not be interpreted as estimates of what an individual patient could receive from a personal-injury lawsuit.
The historical Neurontin litigation was also organized in federal multidistrict proceedings dealing with marketing, sales practices, product liability, and antitrust allegations. Those proceedings should not be confused with claims appearing on legal websites in 2026 concerning newly alleged injuries.
Anyone considering an individual gabapentin claim must also consider the statute of limitations. Filing deadlines differ by state and may depend on when the injury occurred or was discovered.
Gabapentin therefore has a substantial history of litigation in the United States, but the nature of that litigation matters. The strongest documented cases concern Neurontin’s earlier off-label marketing and related economic claims. Newer potential personal-injury theories may develop separately, but they should not be described as an established nationwide settlement program or mass tort unless and until court records support that characterization.
